A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

NCT00046072 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Sepsis
Shock, Septic
Sepsis Syndrome
Septicemia
Infection

Interventions

DRUG: E5564

Sponsor

Eisai Inc.